text: Containment is very good but not great like the Rose 6 or Soldier VI. I didn’t feel my foot coming out of the shoe but I could feel the forefoot upper flex on hard cuts. As you can see below the midsole is raised a little bit above the footbed and there is an extra layer (grey) of fuse.
  Nike basically set a frame of extra fuse around the high pressure areas to keep the foot contained (grey areas) to keep the shoe lightweight but strong. Pretty awesome idea to reinforce only the necessary areas.
  Why tease us with near perfection Nike ? If the traction was even somewhat close to as good as the IV, I probably could have stopped buying shoes for a few years. I really wanted to love these back then but the traction just didn’t work on public indoor courts that get lots of foot traffic. The few games I played on pristine courts, these worked very well and were extremely fun to play in. Since these never made it into my rotation, I never had a dreaded blow out where the upper tore from the midsole. I remember hearing a lot about that back when these released.
  Regardless of performance these are just beautiful to look at and really propelled the trend of 20 colorways per shoe. With new synthetics, Nike created colorways that were never seen before on athletic shoes. Despite not making my rotation I still love collecting these just on aesthetics alone. Nike has tried to duplicate the beauty of the Bruce Lee, Duke, and Chaos colorway in subsequent models but you just can’t recreate art by just using the same color palette; it takes the perfect blend of a silhouette, materials, and a shoe’s place in history to truly make it meaningful.
  If you play on pristine courts, grab the Kobe V and enjoy one of the best looking, head turning lows ever made but if not I suggest looking at other models.
  Lol these came out my freshman year and my cousin (a senior at the time) told me that these are the best and then he pointed at the bottom and said “looks like I won’t be slipping around”. On our super dusty unfinished court that’s exactly what happened.
  I loved my 4’s, but I loved my 5’s even more. I like the low to the ground set up. Any chance you have a nice pair you want to let go for less than retail?cheers
  Like you said the fit is the best ever… the weight and the fit make this shoes feel amazing, as a quick guard back in the day the cushion works great for me, nike made this shoes with a perfect ingridients, not too much in every way, from the way i said it maybe it sounds like the best shoes IMO, but it is, love this shoes so much i wish they retroed it asap so i could grab a couple while i can still playing..
  Traction isn’t terrible it just isn’t as good as the other Kobe’s. Great fun shoe to play in when the floor is clean though. Thanks for reading !
  I remember playing in these during my freshmen year of high school. You and I share the same thoughts on this shoe. Comfortable and almost like the 4, but the traction is a no go (court was too dusty back in my freshmen year). The 4 is the shoe that got everything right from stability, cushoning, traction, I can go on about why the 4 is the best Kobe model to be made IMO. I had the USA colorway for the Kobe 5 and I didn’t like how the traction didn’t work like the Kobe 4. The traction on the 5 didn’t feel consistent for me, but as I grew older, I now find myself wanting to get this shoe again just so I can actually own it and review it myself and play on a pristine court. I for one like playing in older models (even though they’ll separate in time) just because Nike made some great kicks back then and the nostalgia.
  Yep it’s fun to play in older models. All my Kobe’s have held up fine but I don’t expect the I to hold up much longer. Newer doesn’t mean better even if it has the latest and greatest tech. But sorry traction ruins a shoe in a hurry so that’s why that’s weighted most heavily for me.
  Traction is everything for me. I’d rather have the Kobe 5s than the Kobe 11s at this point. Even though DS pair Kobe 5s would a little more expensive, they work out better than the 11s probably. For traction I’d take the 5 in a heartbeat. Hopefully when they remaster kobes. They won’t make em worse just like they did to the 08 hyperdunk and the price will a lil bit friendly (doubt that’s going to happen).
  Look for a vNDS pair for around retail and you’ll be good . Yep traction is the most important part of shoe unless you play on a perfect floor every game
  I’ll most likely do that. 5s seem to be very expensive nowadays. I love older models but people are charging way too much for them. FTB 5 is 320 lmao. also playing in the older releases would most likely not hold up for a specific period of time
  It feels lower to the ground and the forefoot bag is only a met bag so it doesn’t go all the way across the forefoot.
  I asked this question bc I currently wear the Kyrie 1s and was thinking about buying these from a buy and sell fb group; Thank you for your time!
  I like my shoes to fit snug at the forefoot and wear a size 8.5 in the kyrie 1s. Can I get away with wearing a size 8.5 in the kobe 5s?
  
  In a letter to the New England Journal of Medicine, a Massachusetts General Hospital (MGH) research team reports a remarkable treatment response in a patient participating in a clinical trial of a novel immune-system-based cancer therapy. Treatment with an investigational CAR T-cell therapy induced complete remission of a brain metastasis of the difficult-to-treat tumor diffuse large-B-cell lymphoma (DLBCL), which had become resistant to chemotherapy — the first report of a response to CAR T-cells in a central nervous system lymphoma.
  In addition, when a subcutaneous tumor began to recur two months after CAR T-cell therapy and a surgical biopsy was performed, the CAR T-cells spontaneously re-expanded and the tumor again went into remission, and phenomenon that had not previously been reported. While the patient eventually relapsed and died more than a year after CAR T-cell therapy, the brain tumor never recurred.
  “Brain involvement in DLBCL carries a grave prognosis, and the ability to induce a complete and durable response with conventional therapies is rare,” explains Jeremy Abramson, MD, of the MGH Cancer Center , lead author of the letter in the Aug. 24 NEJM. “In addition, all available CAR T-cell trials have excluded patients with central nervous system involvement. This result has implications not only for secondary DLBCL like this case but also for primary central nervous system lymphoma, for which treatment options are similarly limited after relapse and few patents are cured.
  Chimeric antigen receptor (CAR) T-cell therapies utilize a patient’s own T cells that have been genetically engineered to bind to a specific antigen on target cancer cells. This clinical trial sponsored by Juno Therapeutics is testing JCAR017, which targets the CD19 protein expressed on most B-cell leukemias and lymphomas. The most common type of non-Hodgkin lymphoma in adults, DLBCL is an aggressive cancer that can develop in many types of tissue.
  This patient was a 68-year-old woman with DLBCL that had not responded either to conventional chemotherapies or to a stem-cell transplant, a situation that usually leads to a life expectancy of less than six months. After enrolling in the study — a phase 1 trial designed to investigate the safety and antitumor activity of JCAR017 — -she was found to have new lesion in the right temporal lobe of her brain.
  One month after the study treatment — which involves chemotherapy followed by intravenous infusion of JCAR017 — follow-up imaging showed complete remission of the brain lesion. The subcutaneous lesion that recurred two months later disappeared after the biopsy with no further treatment. Blood testing showed an expansion in the numbers of CD19-targeted CAR T-cells that coincided with the tumor’s regression. While re-expansion of CAR T-cells has been reported in response to other immunotherapy drugs, this is the first report of such a response to a biopsy.
  “Typically the drugs we use to fight cancer and other diseases wear off over time,” Abramson explains. “This spontaneous re-expansion after biopsy highlights this therapy as something entirely different, a ‘living drug’ that can re-expand and proliferate in response to biologic stimuli.” He and his co-authors note that discovering the mechanisms behind the reactivation of CAR T-cells could further augment their efficacy.
  Story Source: Materials provided by Massachusetts General Hospital Original written by Whitney Clavin.Note: Content may be edited for style and length.
  
  Response monitoring using fluorodeoxyglucose positron emission tomography acquired as well as | BACE1 Inhibitors for the Treatment of Alzheimer's Disease
  Response monitoring using fluorodeoxyglucose positron emission tomography acquired as well as low dose computed tomography (FDG-PET/CT) textural features has potential in targeted treatment with erlotinib in non-small cell lung cancer (NSCLC) patients. which is directly linked to the FDG-concentration. Typically however it is the relative tissue uptake of FDG that is of interest. The two most significant sources of variation that occur in practice are the amount of injected FDG and the individual size. To pay for these variants at least to 1st order SUV is often used as a member of family way of measuring FDG-uptake. Nevertheless there is certainly increasing fascination with evaluating the global and local-regional heterogeneity of FDG-distribution with feature evaluation with a variety of numerical methods that explain Mouse monoclonal antibody to Hexokinase 1. Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in mostglucose metabolism pathways. This gene encodes a ubiquitous form of hexokinase whichlocalizes to the outer membrane of mitochondria. Mutations in this gene have been associatedwith hemolytic anemia due to hexokinase deficiency. Alternative splicing of this gene results infive transcript variants which encode different isoforms, some of which are tissue-specific. Eachisoform has a distinct N-terminus; the remainder of the protein is identical among all theisoforms. A sixth transcript variant has been described, but due to the presence of several stopcodons, it is not thought to encode a protein. [provided by RefSeq, Apr 2009] the relationships between your gray-level strength of pixels or voxels and their placement within an picture. Nelfinavir Initial validation from the dimension of intratumoral heterogeneity on FDG-PET pictures appears to offer predictive info at pretherapy imaging in several solid tumors. Lately Cook evaluated this problem (13). The purpose of their research was to see whether first-order and high-order textural features on FDG-PET pictures of NSCLC (I) at baseline; (II) at 6 weeks; or (III) the percentage modification between baseline and 6 weeks can predict response or success in individuals treated with erlotinib. They assumed that textural features reflecting heterogeneity on FDG-PET pictures in individuals with NSCLC who are becoming treated with erlotinib are connected with treatment response and success. To verify this hypothesis they examined a inhabitants of 47 individuals calculating: (I) First-order textural features included regular deviation skewness kurtosis first-order entropy and first-order uniformity; (II) high-order features including coarseness comparison busyness and difficulty produced from three-dimensional matrices explaining variations between each Family pet image voxel and its own neighbor were determined considering for every voxel the neighboring voxels in both adjacent planes. The median Operating-system was 14.1 months. Relating to CT RECIST at 12 weeks there have been 21 nonresponders and 11 responders. Response to erlotinib was connected with decreased heterogeneity (first-order regular deviation P=0.01; entropy P=0.001; uniformity P=0.001). At multivariable evaluation high-order comparison at 6 weeks (P=0.002) and Nelfinavir percentage modification in first-order entropy (P=0.03) were independently connected with success. Percentage modification in first-order entropy was also individually connected with treatment response (P=0.01). Yet in this evaluation the texture guidelines were as predictive as the SUV guidelines. Even though the evaluation of Make was limited by a small group of individuals the email address details are promising which is feasible to consider applicability from the strategy in other medical studies so long as the calculation software program of the textural features becomes available after standardization. Reproducibility for 18F-FDG textural features Nelfinavir has been reported to be as good as or even better than the one used for SUV (14). In the work of Cook measurement of all texture parameters showed a good interobserver variability. However other aspects must be elucidated. For instance the clinical resolution of current PET scanners is still in the order of 4 to 5 mm which means that for relatively small lung tumors the partial volume effect will make it challenging to accurately Nelfinavir measure the volume for tumors with a diameter less than 3 cm with low FDG-uptake (15). Assessment of the heterogeneity within the tumor may suffer from this same lack of resolution. Despite the limitation in spatial resolution the measured SUV distribution inside the tumor still (although blurred) contains information about the heterogeneity of the tumor. Statistical methods are therefore necessary for the evaluation of this distribution. A disadvantage of this approach is that it is not clear what type of heterogeneity is correlating with the tumor response. Information would be vital for future development towards prospective use. Relatively small tumors like NSCLC which are evaluated in this study show a strong correlation between total uptake en the size of the tumor. For instance in a perfectly spherical tumor where the uptake decreases as function of the distance to the center the standard deviation of the distribution of the FGD-values will scale with the size of the tumor. In this case both total (or peak) SUV and.
  
  The indwallers speak a conservative group o Arabic dialects. Maist tribes in 'Asir are dividit intae three sub-pairts based on thair geographical location. The tribes o the central heichlands are cried sarat, the tribes o the wastren coastal plain are cried tihama, an the tribes o the eastren desert region o 'Asir are referred tae as badiyah. Thus mony tribes are dividit intae sarat, tihama, an badiyah components.
  
  This is a compilation of four teaching sequences about personal peace. It includes sections on peaceful thoughts; peace poems; peace and conflict; and children in other places and their experiences of peace and conflict. The section on children in other places and their experiences enables places people live in and belong ...